ERBB2 and breast carcinoma: The 21-gene Oncotype DX recurrence score has been used to identify which women with node-negative, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer can safely forgo chemotherapy without increasing the risk of recurrence.